Publications by authors named "M G Bialer"
Article Synopsis
- The 17th Eilat Conference on New Antiepileptic Drugs and Devices was held in Madrid from May 5-8, 2024, focusing on investigational drugs for epilepsy.
- Presentations included advanced clinical compounds with available antiseizure activity data, such as azetukalner, bexicaserin, radiprodil, soticlestat, and STK-001.
- The diversity in these compounds reflects various approaches to developing new treatments for seizures and epilepsy, with some already showing efficacy in clinical trials.
Article Synopsis
- - The Eilat Conference on New Antiepileptic Drugs and Devices, held in Madrid in May 2024, served as a platform for discussing recent advances in therapies for epilepsy and seizures involving scientists, clinicians, and health professionals.
- - Key treatments showcased included AMT-260 (gene therapy for drug-resistant seizures), BHV-7000 (for focal epilepsy), and several others targeting conditions like Dravet syndrome and Lennox-Gastaut syndrome.
- - The conference highlighted innovative drug candidates aimed at improving outcomes for patients with epilepsy, with a focus on drug-resistant cases and mechanisms like potassium channel activation and GABAergic neuron modulation.
Background And Objective: Post-stroke epilepsy represents an important clinical challenge as it often requires both treatment with direct oral anticoagulants (DOACs) and antiseizure medications (ASMs). Levetiracetam (LEV), an ASM not known to induce metabolizing enzymes, has been suggested as a safer alternative to enzyme-inducing (EI)-ASMs in patients treated with DOACs; however, current clinical guidelines suggest caution when LEV is used with DOACs because of possible P-glycoprotein induction and competition (based on preclinical studies). We investigated whether LEV affects apixaban and rivaroxaban concentrations compared with two control groups: (a) patients treated with EI-ASMs and (b) patients not treated with any ASM.
View Article and Find Full Text PDFThe aim of this study was to investigate the comparative antiseizure activity of the -enantiomers of ,-fenfluramine and ,-norfenfluramine and to evaluate the relationship between their concentration in plasma and brain and anticonvulsant activity. ,-Fenfluramine, ,-norfenfluramine and their individual enantiomers were evaluated in the mouse maximal electroshock seizure (MES) test. ,-Fenfluramine, ,-norfenfluramine and their individual -enantiomers were also assessed in the DBA/2 mouse audiogenic seizure model.
View Article and Find Full Text PDFThe effect of fenfluramine and norfenfluramine enantiomers in rodent seizure models and their correlation with the pharmacokinetics of d- and l-fenfluramine in rats have been reported recently. To complement these findings, we investigated the pharmacokinetics of d- and l- norfenfluramine in rat plasma and brain. Sprague-Dawley rats were injected intraperitoneally with 20 mg/kg and 1 mg/kg l- norfenfluramine.
View Article and Find Full Text PDF